Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid TumorsDirk Strumberg, Brian Schwartz, Jeffrey W. Clark et al.|The Oncologist|2007Cited by 418
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerAmit M. Oza, Daniela Matei, Ursula A. Matulonis et al.|Clinical Cancer Research|2019Cited by 90
Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.Ursula A. Matulonis, Daniela Matei, Amit M. Oza et al.|Journal of Clinical Oncology|2016Cited by 8
A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors.Wael A. Harb, Srinivasu Poondru, Ronit Simantov et al.|Journal of Clinical Oncology|2011Cited by 7
Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerAmit M. Oza, Daniela Matei, Ursula A. Matulonis et al.|Unknown|2023Cited by 1